Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Insulin capped at $35 per month for Minnesotans, after settlement with manufacturers
Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three major drug manufacturers.
Minnesota insulin lawsuit: AG Ellison reaches settlement with Novo Nordisk
Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high cost of insulin.
MN Novo Nordisk settlement over insulin pricing [RAW]
Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires Novo Nordisk to offer its insulin products to Minnesotans for no more than $35 a month over the next five years.
Novo Nordisk agrees to cap insulin prices in Minnesota settlement
This story incorporates reporting fromdevdiscourse, WJON and KIMT.Novo Nordisk has settled a lawsuit with Minnesota, agreeing to cap insulin prices at $35 per monthly prescription. This legal resolution addresses the lawsuit initiated by Minnesota Attorney General Keith Ellison,
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
pharmaphorum8d
Lilly preps for rollout of its connected diabetes system
Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular ... currently compatible with three of Lilly's insulin products, including Humalog and ...
Seeking Alpha27d
Lilly seeking to join lawsuit over compounded GLP-1 drugs
products were taken off the shortage list in October. Some of Novo Nordisk's (NVO) semaglutide formulations remain on the list. Lilly (LLY) markets tirzepatide for diabetes as Mounjaro and for ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...
pharmaphorum18d
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge
The strong performance of the diabetes product allowed Lilly to build its fourth quarter sales to $6.11 billion, with help from a supporting case of other products launched in the last few years ...
Pharmabiz1mon
Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio
Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the ...
Investing16d
Eli Lilly's SWOT analysis: stock soars on diabetes drug success, eyes new markets
Competitors are developing their own innovative treatments, which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate ...